Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.65, No.3, p.415-424, 2018 |
||
Title: Novel insights into transcriptional dysregulation in colorectal cancer | ||
Author: Y. FEODOROVA, D. TASHKOVA, I. KOEV, A. TODOROV, G. KOSTOV, K. SIMITCHIEV, V. BELOVEJDOV, R. DIMOV, V. SARAFIAN | ||
Abstract: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Although CRC has been compre- hensively characterized at the molecular level, the tumor heterogeneity hinders the identification of reliable diagnostic, prognostic and predictive biomarkers. Molecular stratification of CRC is based on prevalent gene mutations and transcrip- tion profiles but its significance for clinical practice remains obscure. Indeed, activating mutations in the genes KRAS, NRAS, and BRAF are the only predictive biomarkers for anti-EGFR antibody therapy routinely tested in the clinic for advanced stages of CRC. Gene expression signatures are important for clarifying the molecular mechanisms of CRC development and progression, but only two such tests for predicting recurrence risk are commercially available. The aim of our study was to propose a diagnostic approach based on mutation and gene expression analysis that can be routinely applied in the clinic for defining the most appropriate treatment strategy for each patient. We used qPCR to determine the presence of KRAS mutations and measure the transcription levels of a panel of 26 genes in 24 CRC patients. Statistical analyses were applied to check for associations between clinicopathological and molecular parameters. Our results reveal novel data concerning CRC carcinogenesis: almost universal downregulation of EGFR; differential role of the pro-inflammatory cytokines TNF-α and IL-6; overexpression of the vitamin B12 transporter transcobalamin 1; tumor-suppressor function of SETD2, CA7, and GUCA2B. The practical application of these findings has yet to be clarified. |
||
Keywords: CRC, gene expression, GUCA2B, KRAS | ||
Published online: 16-May-2018 | ||
Year: 2018, Volume: 65, Issue: 3 | Page From: 415, Page To: 424 | |
doi:10.4149/neo_2018_170707N467 |
||
|
download file |
|